Search

CuFeO 2 -modified biochars were prepared through co-precipitation and hydrothermal methods, and the composites had high efficiency removal for tetracycline (TC) from water. The CuFeO 2 -modified biochar with a 2:1 mass ratio of CuFeO 2 to BC450 (CuFeO 2 /BC450=2:1) demonstrated the best adsorption performance. The kinetic process of TC adsorption by CuFeO 2 /BC450=2:1 was well fitted with the intraparticle diffusion model, suggesting that the adsorption process was controlled by film and pore diffusion. Under the condition of neutral pH and 298 K, the maximum adsorption capacity of the Langmuir model of CuFeO 2 /BC450=2:1 was 82.8 mg·g -1 , which was much greater than that of BC450 (13.7 mg·g -1 ) and CuFeO 2 (14.8 mg·g -1 ). The thermodynamic data suggested that TC sorption onto CuFeO 2 /BC450=2:1 was a spontaneous and endothermic process. The removal of TC by CuFeO 2 /BC450=2:1 increased first and then decreased with increasing pH, and the maximum adsorption occurred under the neutral condition. The strong adsorption of TC by CuFeO 2 /BC450=2:1 could be attributed to better porosity, larger specific surface area, and more active sites (e.g., functional groups and charged surfaces). This work provided an efficient magnetic adsorbent for removing antibiotics.

Objective: The purposes of this study were to observe the effects of different treatment strategies, including third-line pemetrexed alone versus its combination with bevacizumab, in patients with advanced epidermal growth factor receptor (EGFR) mutation-positive lung adenocarcinoma, and to analyze the effects of the different medication orders of first- and second-line drugs on third-line efficacy., Patients and Methods: One hundred and sixteen cases of patients with EGFR-positive lung adenocarcinoma who had received third-line pemetrexed alone or in combination with bevacizumab between March 2010 and March 2014 at Guangzhou Institute of Respiratory Diseases, the First Affiliated Hospital of Guangzhou Medical University were analyzed retrospectively. Additionally, all the patients were treated with first-line gemcitabine and cisplatin (GP) chemotherapy and second-line EGFR tyrosine kinase inhibitor (TKI) or with first-line EGFR-TKI and second-line GP chemotherapy., Results: The median survival of 61 cases with third-line pemetrexed monotherapy was 36.22 months, the median survival time of 55 cases with third-line pemetrexed plus bevacizumab was 38.76 months, and there was a significant difference in survival time between the two groups (P=0.04). Subgroup analysis revealed that among the 55 cases with third-line bevacizumab plus pemetrexed treatment, the median survival of 29 patients with first-line GP and second-line EGFR-TKI was 42.80 months, while the median survival of 26 patients with first-line EGFR-TKI and second-line GP was only 34.46 months; additionally, there was a significant difference in the survival time between the two subgroups (P=0.001). Among 61 cases with third-line pemetrexed treatment, the median survival of 34 patients with first-line GP and second-line EGFR-TKI was 38.72 months, while the median survival of 27 patients with first-line EGFR-TKI and second-line GP was only 32.94 months; the survival time of the two subgroups was significantly different (P=0.001)., Conclusions: Regardless of the order of the first- and second-line chemotherapy and TKI therapy, the pemetrexed plus bevacizumab regimen was superior to the pemetrexed monotherapy as the third-line therapy in patients with advanced EGFR-positive lung adenocarcinoma. However, this strategy is worth further investigation in prospective studies.

Objective: To investigate the effect of Zhigancao Decoction (ZD) containing serum on transient outward potassium current (I(to)) in isolated single ventricular myocyte of rabbits., Methods: Single rabbit ventricular myocytes were isolated and divided into 6 groups, the normal group, the non-drug-containing serum group, and the ZD groups, they were treated with normal extracellular fluid alone or with ZD containing serum recording technique was used to observe the changes of I(to)., Results: After treated with 5%, 10%, 20% and 40% ZD containing serum, the I(to) was inhibited and its peak value dropped from (16.1 +/- 1.4) PA/PF to (13.9 +/-1.5) PA/PF, (11.8 +/- 1.9) PA/PF, (8.3 +/- 1.5) PA/PF and (8.2 +/- 1.2) PA/PF respectively, and the effect could be eliminated by elution., Conclusion: ZD containing serum could inhibit the I(to) in isolated ventricular myocytes of rabbits in a concentration-dependent manner, which may be the mechanism of antiarrhythmic action of ZI).

Objective: To investigate the relationship between p53 mutation and the expression of some drug-resistance genes commonly found in lung cancer., Methods: Sixty-six of untreated lung cancers and paracancerous tissues were obtained by surgical resection. Immunohistochemical staining was employed for detection of both mutant p53 and drug-resistance associated proteins (MDR1, MRP1, LRP, TOPO II alpha, GST-pi), PCR-SSCP and RT-PCR were used for detection of mutations of p53 exon 5-8 as well as the expression of mRNAs for the genes coding those drug-resistance associated proteins in 31/66 cases. ATP-TCA assay was also performed simultaneously in 12 out of the 31 cases for evaluation of their reaction in response to chemotherapy., Results: Correlations were found between p53 mutation and expression of either Pgp or MRP1 or GST-pi (P < 0.05). There was a significant correlation between p53 mutation with simultaneous expression of Pgp and MRP1 and drug-resistance to either vinorelbine or carboplatin., Conclusions: The results suggested that p53 mutation in lung cancers was closely correlated with the expression of drug-resistance associated protein which was associated with endogenous resistance to most of chemotherapeutic drugs. It indicated that wild p53 gene therapy might be helpful for treating the endogenous drug resistance of lung cancer in chemotherapeutics.